Heartseed

  • NEWS
  • PIPELINE
  • TECHNOLOGY
  • ABOUT US
    • CEO Message
    • Purpose
    • Company Profile
    • Management
  • Mission & Values
  • IR
    • IR News
    • Management
    • IR Library
    • Stock Information
    • Other Contents
  • CONTACT
  • JP/EN
  1. HOME
  2. NEWS
  3. 2022

2022

2022914

PR Heartseed recognized as the "Most Promising Pipelines (iPSC Therapy) Award" at the APAC Cell and Gene Therapy Excellent Awards 2022.

2022630

Congress Keiichi Fukuda, CEO at Heartseed is speaking at this year's Cell & Gene Therapy World Asia Summit in September 15-16.

2022620

Media Interview with Keiichi Fukuda was published in "Features", Keio University School of Medicine.

2022614

Congress Takehiko Kaneko, CMO at Heartseed, is speaking at this year's webinar by American Physiological Society.

2022614

Congress Takehiko Kaneko, CMO and Head of R&D at Heartseed, is speaking at this year's iPSC Manufacturing Summit in July 26-28.

202267

Media Interview with Takehiko Kaneko, CMO and Head of R&D at Heartseed, was published in RegMedNet.

2022128

Media Heartseed was featured by NHK World's CATCH JAPAN.

2022111

Media An interview with Kikuo Yasui, COO was published in Venture Valuation.

1

COMPANY OVERVIEW

To transform treatment of severe heart failure by delivering cardiac regenerative medicine, Heartseed Inc. was founded in 2015. It has also been developing technologies to expand the access of RM.

Company name
Heartseed Inc.
Head Office
Seavans South Building 5F, 1-2-3 Shibaura, Minato-ku, Tokyo 105-0023, JAPAN
Contact
contact@heartseed.jp

MORE VIEW

MENU

  • Home
  • News
  • PIPELINE
  • TECHNOLOGY
  • About us
  • Mission & Values
  • IR
  • Contacts

language

  • English
  • Japanese

GO TO TOP

Copyright © All Rights Reserved HEARTSEED HEARTSEED